scholarly journals Obstructive Uropathy as a Major Presentation of Ovarian Clear Cell Adenocarcinoma

2008 ◽  
Vol 47 (1) ◽  
pp. 116-119
Author(s):  
Yen-Hua Huang ◽  
Tien-Shan Wei ◽  
Pao-Jen Chen ◽  
Shuenn-Dyh Chang ◽  
Tony Wing-Cheong Chi ◽  
...  
2012 ◽  
Vol 62 (3) ◽  
pp. 216-218 ◽  
Author(s):  
Tomohito Tanaka ◽  
Takayoshi Kanda ◽  
Satoru Munakata ◽  
Shigeki Fujita ◽  
Masahide Ohmichi

2011 ◽  
Vol 0 (0) ◽  
pp. 129-138 ◽  
Author(s):  
Sohei Yamamoto ◽  
Atsuko Kasajima ◽  
Masashi Takano ◽  
Nobuo Yaegashi ◽  
Hiroyuki Fujiwara ◽  
...  

2008 ◽  
Vol 18 (5) ◽  
pp. 934-936 ◽  
Author(s):  
J. A. Rauh-Hain ◽  
R. T. Penson

Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC). Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA. A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission. Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level. Recurrent and refractory OCCA may respond to Sunitinib. Clinical trials are needed to objectively confirm these findings, as benefit may be limited in patients with extensively pretreated tumors


2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 5050-5050
Author(s):  
S. Nishimura ◽  
H. Tsuda ◽  
Y. M. Ito ◽  
K. Ito ◽  
N. Yaegashi ◽  
...  

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16509-e16509 ◽  
Author(s):  
Kazuhiro Takehara ◽  
Haruhisa Konishi ◽  
Atsumi Kojima ◽  
Shinichi Okame ◽  
Yuko Shiroyama ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document